Home > Products > Antibodies > Biosimilars

Research Grade Acimtamig (HB038106)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HB038106
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHuman
IsotypeIgG VH-V-kappa-VH'-V-lambda homodimer
Expression systemMammalian Cells
ClonalityMonoclonal
TargetCD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30, CD16a, CD16A, FCGR3A, Fc-gamma RIII-alpha, FcRIIIa, IgG Fc receptor III-2, Low affinity immunoglobulin gamma Fc region receptor III-A, IGFR3, CD16a antigen, Fc-gamma RIII, FCGR3, Fc-gamma RIIIa, FCG3, FcRIII, FcR-10
Concentration1mg/ml
Endotoxin levelPlease contact the lab for this information.
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G, purified from cell culture supernatant.
AccessionP28908 & P08637
FormLiquid
Storage buffer0.01M PBS,pH7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -2108°C.
Alternate NamesCAS:2738880-26-5
BackgroundAcimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL).
NoteFor research use only. Not for use in clinical or therapeutic applications.
Images
References

Recommendation